Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
Molecular Immunology
|
December 1, 1994
Sequences of heavy and light chain variable regions from four bovine immunoglobulins
K L Armour, P R Tempest, P H Fawcett, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 15, 1995
Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody
R F Graziano, P R Tempest, P White, et al.
Oncogene
|
June 1, 1988
Characterization of the mouse met proto-oncogene
A M Chan, H W King, E A Deakin, et al.
Protein Engineering
|
December 1, 1994
Efficient generation of a reshaped human mAb specific for the alpha toxin of Clostridium perfringens
P R Tempest, P White, E D Williamson, et al.
Journal of Immunological Methods
|
September 15, 1999
A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy
J E Thompson, T J Vaughan, A J Williams, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
Molecular Immunology
|
December 1, 1994
Sequences of heavy and light chain variable regions from four bovine immunoglobulins
K L Armour, P R Tempest, P H Fawcett, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 15, 1995
Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody
R F Graziano, P R Tempest, P White, et al.
Oncogene
|
June 1, 1988
Characterization of the mouse met proto-oncogene
A M Chan, H W King, E A Deakin, et al.
Protein Engineering
|
December 1, 1994
Efficient generation of a reshaped human mAb specific for the alpha toxin of Clostridium perfringens
P R Tempest, P White, E D Williamson, et al.
Journal of Immunological Methods
|
September 15, 1999
A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy
J E Thompson, T J Vaughan, A J Williams, et al.
Page
of 3